Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Sionna Therapeutics director Laurie Stelzer received a grant of non-qualified stock options covering 17,340 shares of common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting, subject to her continued service. Following this grant, Stelzer holds options for 17,340 underlying shares directly, reflecting a routine equity-based compensation award rather than an open-market share purchase or sale.
Sionna Therapeutics director Joanne L. Viney received a grant of a non-qualified stock option covering 17,340 shares of common stock. The option has an exercise price of $36.73 per share and expires on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna’s next annual meeting, subject to her continued service as a director. Following this award, she holds options representing the right to acquire 17,340 shares directly. This is a compensation-related award, not an open-market purchase or sale.
Sionna Therapeutics director Peter A. Thompson reported a grant of 17,340 non-qualified stock options linked to Sionna Therapeutics, Inc. common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036. They vest in full on the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on his continued service. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, any securities or economic benefits from these options are to be transferred so that the economic benefit is provided to OrbiMed Private Investments VIII, LP.
Sionna Therapeutics, Inc. reported a Form 4 showing a grant of a non-qualified stock option covering 17,340 shares of common stock. The option has an exercise price of $36.73 per share and expires on June 16, 2036.
According to the footnotes, Dr. Resnick holds this option for the benefit of RA Capital-managed vehicles, and any net cash or stock from exercise will offset advisory fees owed to those funds. RA Capital Management, affiliated funds, and their principals disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest.
Sionna Therapeutics director Marcella K. Ruddy received a new equity award. She was granted a non-qualified stock option covering 17,340 shares of Common Stock at an exercise price of $36.73 per share, expiring on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics, Inc.’s next annual meeting, subject to her continued service through the vesting date. Following this grant, she holds 17,340 option shares directly.
Sionna Therapeutics director Joshua Resnick reported a grant of non-qualified stock options linked to 17,340 shares of Common Stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036. They vest in full on the earlier of June 17, 2027 or the date of the next annual meeting, contingent on his continued board service. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising these options is turned over for the benefit of RA Capital’s funds and a managed account, and Resnick disclaims beneficial ownership of the options and underlying shares.
Sionna Therapeutics reported a new stock option grant connected to director Harold Edward Fleming’s board service. The award covers 17,340 Non-Qualified Stock Options with an exercise price of $36.73 per share, expiring on June 16, 2036. According to the disclosure, Fleming has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all rights in the option and the underlying shares. The option vests in full on the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to continued board service.
Sionna Therapeutics director Paul J. Clancy received a new stock option award. He was granted a non-qualified option for 17,340 shares of common stock at an exercise price of $36.73 per share, expiring on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics' next annual meeting, as long as he continues to serve through that vesting date. Following this grant, the filing shows Clancy holding 17,340 option shares directly.
Sionna Therapeutics director Bruce Booth received a grant of 17,340 non-qualified stock options to buy common stock at $36.73 per share. The options expire on June 16, 2036 and vest in full on the earlier of June 17, 2027 or the next annual meeting, subject to his continued service. Any proceeds from future sales of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except for any pecuniary interest.
Sionna Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. Stockholders voted on the election of four Class II director nominees and the ratification of the company’s independent registered public accounting firm.
All four Class II director nominees—H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.—were elected to serve until the 2029 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 45,142,330 shares of common stock outstanding as of the April 21, 2026 record date, and a quorum was present at the meeting, allowing these proposals to be approved.